Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 40

1.
2.

Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial.

du Bois A, Kristensen G, Ray-Coquard I, Reuss A, Pignata S, Colombo N, Denison U, Vergote I, Del Campo JM, Ottevanger P, Heubner M, Minarik T, Sevin E, de Gregorio N, Bidziński M, Pfisterer J, Malander S, Hilpert F, Mirza MR, Scambia G, Meier W, Nicoletto MO, Bjørge L, Lortholary A, Sailer MO, Merger M, Harter P; AGO Study Group led Gynecologic Cancer Intergroup/European Network of Gynaecologic Oncology Trials Groups Intergroup Consortium.

Lancet Oncol. 2016 Jan;17(1):78-89. doi: 10.1016/S1470-2045(15)00366-6. Epub 2015 Nov 16.

PMID:
26590673
3.

Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial.

Oza AM, Cook AD, Pfisterer J, Embleton A, Ledermann JA, Pujade-Lauraine E, Kristensen G, Carey MS, Beale P, Cervantes A, Park-Simon TW, Rustin G, Joly F, Mirza MR, Plante M, Quinn M, Poveda A, Jayson GC, Stark D, Swart AM, Farrelly L, Kaplan R, Parmar MK, Perren TJ; ICON7 trial investigators.

Lancet Oncol. 2015 Aug;16(8):928-36. doi: 10.1016/S1470-2045(15)00086-8. Epub 2015 Jun 23.

4.

Tissue microRNAs as predictors of outcome in patients with metastatic colorectal cancer treated with first line Capecitabine and Oxaliplatin with or without Bevacizumab.

Boisen MK, Dehlendorff C, Linnemann D, Nielsen BS, Larsen JS, Osterlind K, Nielsen SE, Tarpgaard LS, Qvortrup C, Pfeiffer P, Holländer NH, Keldsen N, Hansen TF, Jensen BB, Høgdall EV, Jensen BV, Johansen JS.

PLoS One. 2014 Oct 15;9(10):e109430. doi: 10.1371/journal.pone.0109430. eCollection 2014.

5.

Primary tumor location and bevacizumab effectiveness in patients with metastatic colorectal cancer.

Boisen MK, Johansen JS, Dehlendorff C, Larsen JS, Osterlind K, Hansen J, Nielsen SE, Pfeiffer P, Tarpgaard LS, Holländer NH, Keldsen N, Hansen TF, Jensen BB, Jensen BV.

Ann Oncol. 2013 Oct;24(10):2554-9. doi: 10.1093/annonc/mdt253. Epub 2013 Jul 17.

PMID:
23864097
6.

Bevacizumab plus chemotherapy continued beyond first progression in patients with metastatic colorectal cancer previously treated with bevacizumab plus chemotherapy: ML18147 study KRAS subgroup findings.

Kubicka S, Greil R, André T, Bennouna J, Sastre J, Van Cutsem E, von Moos R, Osterlund P, Reyes-Rivera I, Müller T, Makrutzki M, Arnold D; ML18147 study investigators including AIO, GERCOR, FFCD, UNICANCER GI, TTD, BGDO, GEMCAD, and AGMT groups.

Ann Oncol. 2013 Sep;24(9):2342-9. doi: 10.1093/annonc/mdt231. Epub 2013 Jul 12.

PMID:
23852309
7.

A randomized phase III trial on maintenance treatment with bevacizumab alone or in combination with erlotinib after chemotherapy and bevacizumab in metastatic colorectal cancer: the Nordic ACT Trial.

Johnsson A, Hagman H, Frödin JE, Berglund A, Keldsen N, Fernebro E, Sundberg J, De Pont Christensen R, Garm Spindler KL, Bergström D, Jakobsen A.

Ann Oncol. 2013 Sep;24(9):2335-41. doi: 10.1093/annonc/mdt236. Epub 2013 Jun 19.

PMID:
23788755
8.

Panitumumab and pegylated liposomal doxorubicin in platinum-resistant epithelial ovarian cancer with KRAS wild-type: the PaLiDo study, a phase II nonrandomized multicenter study.

Steffensen KD, Waldstrøm M, Pallisgård N, Lund B, Bergfeldt K, Wihl J, Keldsen N, Marth C, Vergote I, Jakobsen A.

Int J Gynecol Cancer. 2013 Jan;23(1):73-80. doi: 10.1097/IGC.0b013e3182775fae.

PMID:
23211422
9.

Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial.

Bennouna J, Sastre J, Arnold D, Österlund P, Greil R, Van Cutsem E, von Moos R, Viéitez JM, Bouché O, Borg C, Steffens CC, Alonso-Orduña V, Schlichting C, Reyes-Rivera I, Bendahmane B, André T, Kubicka S; ML18147 Study Investigators.

Lancet Oncol. 2013 Jan;14(1):29-37. doi: 10.1016/S1470-2045(12)70477-1. Epub 2012 Nov 16.

PMID:
23168366
10.

Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study.

Tveit KM, Guren T, Glimelius B, Pfeiffer P, Sorbye H, Pyrhonen S, Sigurdsson F, Kure E, Ikdahl T, Skovlund E, Fokstuen T, Hansen F, Hofsli E, Birkemeyer E, Johnsson A, Starkhammar H, Yilmaz MK, Keldsen N, Erdal AB, Dajani O, Dahl O, Christoffersen T.

J Clin Oncol. 2012 May 20;30(15):1755-62. doi: 10.1200/JCO.2011.38.0915. Epub 2012 Apr 2.

PMID:
22473155
11.

A phase 3 trial of bevacizumab in ovarian cancer.

Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, Carey MS, Beale P, Cervantes A, Kurzeder C, du Bois A, Sehouli J, Kimmig R, Stähle A, Collinson F, Essapen S, Gourley C, Lortholary A, Selle F, Mirza MR, Leminen A, Plante M, Stark D, Qian W, Parmar MK, Oza AM; ICON7 Investigators.

N Engl J Med. 2011 Dec 29;365(26):2484-96. doi: 10.1056/NEJMoa1103799. Erratum in: N Engl J Med. 2012 Jan 19;366(3):284.

12.

Impact of ABCB1 variants on neutrophil depression: a pharmacogenomic study of paclitaxel in 92 women with ovarian cancer.

Bergmann TK, Brasch-Andersen C, Gréen H, Mirza MR, Skougaard K, Wihl J, Keldsen N, Damkier P, Peterson C, Vach W, Brøsen K.

Basic Clin Pharmacol Toxicol. 2012 Feb;110(2):199-204. doi: 10.1111/j.1742-7843.2011.00802.x. Epub 2011 Oct 25.

13.

Plasma TIMP-1 levels and treatment outcome in patients treated with XELOX for metastatic colorectal cancer.

Frederiksen C, Qvortrup C, Christensen IJ, Glimelius B, Berglund A, Jensen BV, Nielsen SE, Keldsen N, Nielsen HJ, Brünner N, Pfeiffer P.

Ann Oncol. 2011 Feb;22(2):369-75. doi: 10.1093/annonc/mdq354. Epub 2010 Jul 19.

PMID:
20643864
14.

A phase II study of combination chemotherapy in early relapsed epithelial ovarian cancer using gemcitabine and pegylated liposomal doxorubicin.

Mirza MR, Lund B, Lindegaard JC, Keldsen N, Mellemgaard A, Christensen RD, Bertelsen K.

Gynecol Oncol. 2010 Oct;119(1):26-31. doi: 10.1016/j.ygyno.2010.06.022. Epub 2010 Jul 17.

PMID:
20638711
15.

Impact of CYP2C8*3 on paclitaxel clearance: a population pharmacokinetic and pharmacogenomic study in 93 patients with ovarian cancer.

Bergmann TK, Brasch-Andersen C, Gréen H, Mirza M, Pedersen RS, Nielsen F, Skougaard K, Wihl J, Keldsen N, Damkier P, Friberg LE, Peterson C, Vach W, Karlsson MO, Brosen K.

Pharmacogenomics J. 2011 Apr;11(2):113-20. doi: 10.1038/tpj.2010.19. Epub 2010 Apr 6.

PMID:
20368717
16.

A randomized study comparing short-time infusion of oxaliplatin in combination with capecitabine XELOX(30) and chronomodulated XELOX(30) as first-line therapy in patients with advanced colorectal cancer.

Qvortrup C, Jensen BV, Fokstuen T, Nielsen SE, Keldsen N, Glimelius B, Bjerregaard B, Mejer J, Larsen FO, Pfeiffer P.

Ann Oncol. 2010 Jan;21(1):87-91. doi: 10.1093/annonc/mdp272. Epub 2009 Jul 21.

PMID:
19622596
17.

Half body irradiation of patients with multiple bone metastases: a phase II trial.

Berg RS, Yilmaz MK, Høyer M, Keldsen N, Nielsen OS, Ewertz M.

Acta Oncol. 2009;48(4):556-61. doi: 10.1080/02841860802488128.

PMID:
18979285
18.

A randomized phase III multicenter trial comparing irinotecan in combination with the Nordic bolus 5-FU and folinic acid schedule or the bolus/infused de Gramont schedule (Lv5FU2) in patients with metastatic colorectal cancer.

Glimelius B, Sørbye H, Balteskard L, Byström P, Pfeiffer P, Tveit K, Heikkilä R, Keldsen N, Albertsson M, Starkhammar H, Garmo H, Berglund A.

Ann Oncol. 2008 May;19(5):909-14. doi: 10.1093/annonc/mdm588. Epub 2008 Jan 21.

PMID:
18209013
19.

[Picture of the month: vena cava superior syndrome].

El-Galaly TC, Keldsen N.

Ugeskr Laeger. 2007 Sep 10;169(37):3118. Danish. No abstract available.

PMID:
17915351
20.

A phase II study of UFT and Leucovorin in combination with mitomycin C in patients with metastatic colorectal cancer.

Gyldenkerne N, Glimelius B, Frödin JE, Kjaer M, Pfeiffer P, Hansen F, Keldsen N, Sandberg E, Jakobsen A.

Acta Oncol. 2004;43(3):276-9.

PMID:
15244251

Supplemental Content

Loading ...
Support Center